Our clinical stage pipeline consists of two novel dopamine-somatostatin chimeric compounds. TBR-760 for the treatment of non-functioning pituitary adenomas (NFPAs) and TBR-065 for additional rare endocrine diseases.
NFPAs are pituitary tumors that disrupt critical structures in the surrounding area of the brain due to mass effect. They may cause vision loss, compression of the carotid artery leading to stroke, cranial nerve palsies, intractable headaches or hormone deficiencies. Currently there are no approved medical therapies to treat these tumors and patients must undergo invasive trans-sphenoidal surgery (TSS) and/or damaging radiation to remove or shrink the tumor.
Tiburio’s TBR-760 is a potential breakthrough in the treatment of NFPA. TBR-760, a dopamine-somatostatin chimeric molecule, inhibits NFPA cell proliferation and has the potential to shrink or halt tumor growth. Tiburio expects to move TBR-760 into a Phase 2 clinical trial in patients with NFPA in the second half of 2020.